Loading...
XNAS
BNTC
Market cap308mUSD
Oct 08, Last price  
8.75USD
1D
-2.67%
1Q
-34.80%
Jan 2017
-97.76%
IPO
-99.57%
Name

Benitec Biopharma Inc

Chart & performance

D1W1MN
XNAS:BNTC chart
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
115.12%
Rev. gr., 5y
-54.69%
Revenues
0
315,844257,063172,314133,014154,387333,722504,449956,152630,504258,520195,8824,400,57317,448,02697,00059,00073,00075,000000
Net income
-46m
L+20.12%
-2,154,921-2,482,041-1,818,799-4,083,384-3,482,657-4,241,523-5,937,833-10,179,799-6,712,750-13,805,243-3,347,056-6,293,9851,823,803-8,274,000-13,882,000-18,208,000-19,562,000-21,751,000-37,917,000-45,546,000
CFO
-17m
L-29.97%
-1,486,735-2,760,978-1,584,767-2,051,824-3,130,419-3,257,579-3,030,230-9,043,606-9,692,000-20,208,000-8,304,000-9,794,0004,790,000-7,535,000-12,832,000-15,899,000-18,012,000-19,403,000-23,588,000-16,518,000
Dividend
Jun 01, 20180.003 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.

Key people

Sophie Mukadam
Chief Operating Officer · since 2025
Jerel Banks
Executive Chairman of the Board, Chief Executive Officer · since 2018
Megan Boston
Chief Financial Officer, Executive Director, Secretary · since 2025
J. Kevin Buchi
Independent Director · since 2013
Peter Francis
Independent Director · since 2017
Sharon Mates
Independent Director · since 2025
Edward Smith
Independent Director · since 2020
URL
https://www.benitec.com
IPO date
Jul 11, 2012
Employees
18
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑062025‑062024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT